The content on this site is intended for healthcare professionals only
Video
ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unrese...
Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland
27 Sep 2022
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced br...
Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
21 Sep 2022
Cancer survivors' stories: An African perspective
Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation
15 Sep 2022
ESMO 2022: Breast and ovarian trial analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
14 Sep 2022
Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA
14 Sep 2022
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible loca...
Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York Cit...
14 Sep 2022
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
12 Sep 2022
Ideal duration of androgen deprivation therapy with post-operative radiotherapy ...
Prof Chris Parker - Institute of Cancer Research, Sutton, UK
12 Sep 2022
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC
Dr Silvia Novello - University of Turin, Turin, Italy
12 Sep 2022
ESMO 2022: Renal roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
12 Sep 2022
Fruquintinib provides improvement in overall survival for refractory mCRC
Dr Nageshwara Arvind Dasari - MD Anderson Cancer Center, Houston, USA
12 Sep 2022
ESMO 2022: Breast cancer highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
12 Sep 2022